Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Mometasone Furoate Nasal Spray in Pediatric Perennial Allergic Rhinitis
NCT01165424Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Apr 2010
- Primary completion
- Dec 2010
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of mometasone furoate nasal spray in perennial allergic rhinitis (PAR), sponsored by Organon & Co. Primary endpoint: Number of Participants With Adverse Events and Adverse Drug Reactions at 24 weeks. Started Apr 2010; status: completed.
02
Drugs
mometasone furoate nasal spray
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT01165424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01165424.